Tocilizumab Other names: Atlizumab

Active ingredient description

Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L04AC07 Tocilizumab L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC07

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
RoACTEMRA Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
ACTEMRA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
RoACTEMRA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 375823-41-9
DrugBank Drug: DB06273
KEGG Drug: D02596
RxNorm Ingredient: 612865
SNOMED-CT Concept: 444648007
Tocilizumab (substance)
UNII Identifier: I031V2H011
TOCILIZUMAB

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.